SeaStar Medical to Present at Noble Capital Markets' NobleCon20 on December 4, 2024
SeaStar Medical to Present at Noble Capital Markets' NobleCon20 on December 4, 2024
SeaStar Medical is a commercial-stage medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical's novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit or visit us on LinkedIn or X.DENVER, Nov. 26, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will present a company overview at NobleCon20, Noble Capital Markets' 20th Annual Emerging Growth Equity Conference, on Wednesday, December 4 at 12:00 p.m. Eastern time (9:00 a.m. Pacific time). The conference is being held in Boca Raton, Fla.
丹佛，2024年11月26日（环球新闻社）-- SeaStar 医疗控股公司（纳斯达克：ICU）是一家处于商业阶段的医疗器械公司，正在开发专有解决方案，以减少超炎症对重要器官的影响。宣布管理层将于12月4日星期三下午12:00（东部时间9:00太平洋时间）在Noble Capital Markets第20届新兴成长股权会议NobleCon20上进行公司概况介绍。该会议将于佛罗里达州博卡拉顿举行。
A webcast of the presentation will be available beginning December 5 on the Company website and will be archived for 90 days.
演示的网络视频将于12月5日开始在公司网站上提供，并将存档90天。
About SeaStar Medical
关于SeaStar Medical
SeaStar Medical is a commercial-stage medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical's novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit or visit us on LinkedIn or X.
SeaStar Medical是一家商业化阶段的医疗科技公司，正在重新定义体外疗法如何减少对重要器官的过度炎症的后果。 SeaStar Medical的新颖技术依靠科学和创新为危重病患者提供挽救生命的解决方案。该公司正在开发和商业化细胞定向的体外疗法，以靶向驱动全身性炎症的效应细胞，导致直接组织损伤，并分泌一系列促炎性细胞因子，以启动和传播不平衡的免疫反应。有关更多信息，请访问。 或访问我们的LinkedIn主页或X.
Contact:
联系方式：
Alliance Advisors IR
Jody Cain
(310) 691-7100
Jcain@allianceadvisors.com
联盟顾问IR
Jody Cain
(310) 691-7100
Jcain@allianceadvisors.com
# # #
# # #
